Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients With Mild-to-Moderate Ulcerative Colitis

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 08 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VE 202 (Primary) ; Vancomycin
Indications Ulcerative colitis
Focus Adverse reactions; Proof of concept; Therapeutic Use
Acronyms COLLECTiVE202
Sponsors Vedanta Biosciences

Most Recent Events

12 Sep 2025 Status changed from active, no longer recruiting to discontinued.
13 Aug 2025 According to Vedanta Biosciences media release, Analyses of bacterial colonization, histological findings, and immune responses are ongoing and will be shared in future scientific forums.
30 Apr 2025 According to a PureTech Health media release, topline results from this study anticipated in 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com